Technology
Health
Pharmaceutical

KemPharm

$1.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-5.05%) Today
-$0.03 (-1.60%) After Hours

Why Robinhood?

You can buy or sell KemPharm and other stocks, options, ETFs, and crypto commission-free!

About

KemPharm, Inc. Common Stock, also called KemPharm, is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Read More It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Employees
33
Headquarters
Celebration, Florida
Founded
2006
Market Cap
49.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
179.72K
High Today
$2.02
Low Today
$1.85
Open Price
$2.02
Volume
169.30K
52 Week High
$8.00
52 Week Low
$1.71

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
2015 IPO
US
North America

News

Seeking AlphaMar 18

KemPharm: Will Optimism Win?

However, a KP415 deal remains the primary value driver for KMPH stock. It will solve KemPharm's cash burn question, and maybe put some cash into the company's bank account. First, I'd like to write a few words about the presentation on Apadaz commercialization progress given on Wednesday 3/13, and then move to KP415, an ADHD prodrug that is KemPharm's flagship product. The Apadaz Update For readers just joining the discussion, Apadaz is a hydrocodone/acetaminophen prodrug that is designed to limit abuse ...

50
Seeking AlphaMar 13

KemPharm down 6% premarket on Apadaz coverage update

Thinly traded nano cap KemPharm (NASDAQ:KMPH) slips 6% premarket, albeit on only 420 shares, on the heels of its update on formulary adoption of pain med APADAZ (benzhydrocodone and acetaminophen).

51
Seeking AlphaFeb 28

KemPharm (KMPH) CEO Travis Mickle on Q4 2018 Results - Earnings Call Transcript

KemPharm (NASDAQ:KMPH) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Jason Rando - Investor Relations, Tiberend Strategic Advisors, Inc. Travis Mickle - President & Chief Executive Officer LaDuane Clifton - Chief Financial Officer Rusty Johnson - Chief Business Officer Conference Call Participants Dan Busby - RBC Capital Markets Scott Henry - Roth Capital Partners Operator Good day, ladies and gentlemen, and welcome to the KemPharm Fourth Quarter and Year End 2...

138

Earnings

-$1.77
-$1.25
-$0.73
-$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.